Synthego has launched a genome engineering service for induced pluripotent stem (iPS) cells, an expansion of automated cell editing capabilities that is designed to achieve extremely high editing efficiency of iPS cells at an industrial scale, and address a longtime challenge in research and drug development—the dearth of high-quality, physiologically relevant biological models needed for translational medicine. [Synthego]
Synthego has launched a genome engineering service for induced pluripotent stem (iPS) cells, an expansion of automated cell editing capabilities that is designed to achieve extremely high editing efficiency of iPS cells at an industrial scale, and address the dearth of high-quality, physiologically relevant biological models needed for translational medicine . . .
